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Increased risk of developing autoimmune manifestations has been identified in different 
primary immunodeficiencies (PIDs). In such conditions, autoimmunity and immune 
deficiency represent intertwined phenomena that reflect inadequate immune function. 
Autoimmunity in PIDs may be caused by different mechanisms, including defects of tol-
erance to self-antigens and persistent stimulation as a result of the inability to eradicate 
antigens. This general immune dysregulation leads to compensatory and exaggerated 
chronic inflammatory responses that lead to tissue damage and autoimmunity. Each 
PID may be characterized by distinct, peculiar autoimmune manifestations. Moreover, 
different pathogenetic mechanisms may underlie autoimmunity in PID. In this review, the 
main autoimmune manifestations observed in different PID, including humoral immuno-
deficiencies, combined immunodeficiencies, and syndromes with immunodeficiencies, 
are summarized. When possible, the pathogenetic mechanism underlying autoimmunity 
in a specific PID has been explained.
Keywords: autoimmunity, immunodeficiency, autoimmune hemolytic anemia, immune thrombocytopenia, 
systemic lupus erytematous
inTRODUCTiOn
Immunodeficiencies and autoimmunity may be considered two opposite conditions, deriving from 
different alterations of the immune system. However, the evidence that primary immunodeficiencies 
(PIDs) are often associated with different autoimmune manifestations suggests that they could share 
common pathogenetic mechanisms, which result in a broad immune dysregulation.
Immune system becomes self-tolerant through two main mechanisms called central and periph-
eral tolerance. As for T cells, central tolerance takes place within the thymus and is mediated by 
medullary thymic epithelial cells (mTEC), which express tissue-specific antigens under the control 
of the the transcription factor autoimmune regulator (AIRE) (1–3). Developing T-cells recognizing 
self-antigens receive a signal to die via programed cell death and, thereby, are deleted, through nega-
tive selection, from the T-cell repertoire (4, 5). As for B cells, negative selection of autoreactive cells 
takes place within the bone-marrow. Different mechanisms, including immunological ignorance, 
anergy, and suppression through regulatory T cells (Treg) are implicated in the control of self-
reactive cells, which escape central tolerance and reach the periphery. For example, the ligation of 
T-cell receptor (TCR), in the absence of costimulatory molecules, makes the cells inable to express 
effector functions like cytokine secretion, leading to anergy (6). The control of the expression of the 
costimulatory molecules CD80 and CD86 is a major mechanism of peripheral tolerance (6).
In some cases, the inability to eradicate foreign antigens may lead to an exaggerated chronic 
inflammatory responses and autoimmunity (7–10), through several mechanisms, including 
TABLe 1 | Autoimmune manifestations in humoral immunodeficiencies.
 1. SIgAD
 Juvenile idiopathic arthritis
  Rheumatoid arthritis
  ITP, AHA
  IBD
  Sjogren’s disease
  Polyarteritis nodosa
  SLE
  Celiac disease
  T1D
 2. CVID
  ITP, AHA
  SLE
  IBD
 3. PRKCD deficiency
  Glomerulonephritis
  Polychondritis
  Antiphospholipid syndrome
  LES
 4. LRBA deficiency
  IBD
  AHA, ITP
  Granulomatous-lymphocytic interstitial lung disease
  T1D
  Neutropenia
  Chronic autoimmune hepatitis
  Eczema
  Uveitis
  Alopecia
 5. Hyper-IgM syndrome
  IBD
  Seronegative arthritis
  Hypothyroidism
  SLE
  Autoimmune hepatitis
  ITP, AHA
  T1D
  Uveitis
SIgAD, selective IgA deficiency; ITP, immune thrombocytopenia, AHA, autoimmune 
hemolytic anemia; IBD, inflammatory bowel disease; SLE, systemic lupus eritematous; 
T1D, type 1 diabetes mellitus; CVID, common variable immunodeficiency.
TABLe 2 | Autoimmune manifestations in combined immunodeficiencies 
and in syndromes with immunodeficiency.
 1. RAG-1/2 deficiency RMRP, ADA, IL2RG, Artemis, DNA ligase IV, ZAP70, 
and IL7Ra deficiency
  Omenn syndrome (erythrodermia, alopecia, hepatosplenomegaly, and 
lymphoadenopathy)
 2. PNP-deficiency, and mutations of ADA, DNA ligase IV, Cernunnos,  
ORAI1 and STIM1, and hypomorphic RAG1 mutations
  AHA, ITP
 3. Wiskott–Aldrich
  AHA
  Autoimmune neutropenia
  Vasculitis
  IgA nephropathy
  Polyarthritis
  IBD
 4. DiGeorge syndrome
  ITP, AHA
  Autoimmune arthritis
  Autoimmune hepatitis
  Vitiligo
  IDB
  Autoimmune endocrinopathy
 5. Ataxia telangiectasia
  Psoriasis
  Autoimmune thyroid disease
 6. STAT1 gain of function
  Autoimmune thyroid disease
  IPEX-like phenotype (eczema, enteropathy, T1D, hypothyroidism, and 
growth hormone insufficiency)
 7. STAT3 gain of function
  Early onset autoimmunity (neonatal diabetes, enteropathy, desquamative 
interstitial pneumonitis, and posterior uveitis)
ITP, immune thrombocytopenia; AHA, autoimmune hemolytic anemia;  
IBD, inflammatory bowel disease.
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molecular mimicry, by-stander activation, epitope spreading, and 
cryptic antigens.
Each PID is characterized by distinct, peculiar autoimmune 
manifestations (Tables 1 and 2), but the mechanisms may differ.
In this review, we will describe the main autoimmune mani-
festations observed in different PIDs, including humoral immu-
nodeficiencies, combined immunodeficiencies, and syndromes 
with immunodeficiencies, and, when possible, we will try to 
explain the pathogenetic mechanism underlying autoimmunity 
in a specific PID.
AUTOiMMUniTY in HUMORAL 
iMMUnODeFiCienCieS
Selective igA Deficiency
Selective IgA deficiency (SIgAD) is the most common 
PID in humans (11). According to European Society for 
Immuno deficiencies (ESID) criteria, SIgAD is defined by the 
presence of serum IgA levels <0.07  g/l in the absence of IgG 
and IgM deficiencies, after the age of 4 years (12). Patients with 
SIgAD have an increased risk to develop allergies and autoim-
mune manifestations, including juvenile idiopathic arthritis, 
rheumatoid arthritis, thrombocytopenic purpura, hemolytic 
anemia, inflammatory bowel disease (IBD), Sjogren’s disease, 
polyarteritis nodosa, systemic lupus erythematosus (SLE), 
celiac disease, and insulin-dependent diabetes mellitus (T1D) 
(Table 1) (13). Little is known about the pathogenesis of SIgAD 
and the predisposition to autoimmunity in these patients. 
Specific human leukocyte antigen (HLA) haplotypes, including 
8.1, DR7, DQ2, DR1, and DQ5 have been identified in patients 
with SIgAD at higher risk autoimmune diseases (14), such as 
SLE, autoimmune thyroiditis, and celiac disease. In a recent 
study, the identification of single nucleotide polymorphisms 
in the IF1H1 gene encoding for an interferon inducible RNA 
helicase 1 protein and of a mutation in the CLEC16A gene in 
SIgAD patients has been associated with the development of 
autoimmune manifestations (14). Jacob et al. hypothesized that 
IgA exerts a protective role against autoimmunity. In particular, 
the interaction between the Fc fragment of IgA receptor and the 
immunoreceptor tyrosine-based activation motif deactivates the 
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pathways of immune response carrying this motif through a par-
tial phosphorylation (15). Moreover, the evidence of antibodies 
to bovine milk proteins in over 60% of IgA deficient patients may 
help explaining the association between SIgAD and inflamma-
tory diseases of gastrointestinal tract (16, 17).
Common variable immunodeficiency
Common Variable immunodeficiency (CVID) is a heterogene-
ous group of disorders characterized by a primary antibody 
deficiency, usually manifesting between the second and fourth 
decades of life with a mean age at onset of 26.3 years (18). It is 
the second most common immunodeficiency with an estimated 
prevalence ranging from 0.073 to 0.977 living patients per 100,000 
inhabitants (19). According to the ESID diagnostic criteria, CVID 
should be taken into account in presence of a marked decrease 
of IgG and IgA with or without low IgM levels (measured at least 
twice; <2SD of the normal levels for their age) (http://esid.org/
Working-Parties/Registry/Diagnosis-criteria). Moreover, all of 
the following criteria should be fullfilled: poor antibody response 
to vaccines (and/or absent isohemagglutinins) or low switched 
memory B cells (<70% of age-related normal value); secondary 
causes of hypogammaglobulinaemia have been excluded diagno-
sis is established after the 4th year of life; no evidence of profound 
T-cell deficiency (http://esid.org/Working-Parties/Registry/
Diagnosis-criteria). More than 25% of CVID patients develop 
autoimmune complications (18, 20). Other medical conditions 
may include gastrointestinal infectious or inflammatory disease, 
lymphadenopathy, splenomegaly, and hematological malignan-
cies (21). Cytopenia is the most common manifestation. Immune 
thrombocytopenia (ITP) has been found in up to 14% of patients 
and autoimmune hemolytic anemia (AHA) in up to 7% (22). In 
most cases (about 60%), the cytopenia precedes the identifica-
tion of hypogammaglobulinemia (23). SLE has been reported 
in some rare CVID patient (24), predominantly females (89%). 
In about 50% of patients, CVID developed within 5 years of the 
diagnosis of SLE (24). Some patients experience an improvement 
in SLE symptoms when hypogammaglobulinemia appears (24). 
Hypogammaglobulinemia can develop because of the use of 
immunosuppressive treatment (i.e., corticosteroids or immuno-
suppressants). Unlike CVID, the cessation of therapy should solve 
hypogammaglobulinaemia. Nevertheless, in some occasion, the 
duration of post-cessation hypogammaglobulinaemia can be 
very prolonged, making difficult to understand its origin (25). 
IBD has been reported in 6–10% of CVID patients (Table 1) (22). 
Many different alterations could help explain the predisposition 
to autoimmune manifestations. In a subgroup of CVID patients, 
IL-7 levels were found to be increased (26, 27). IL-7 plays a 
key role in the expansion of autoreactive T-cell clones in the 
lymphopenic host (26, 27). Moreover, reduced levels of switched 
memory B cells and increased levels of activated CD21-low B 
cells have been associated with autoimmune manifestations in 
CVID. Increased levels of CD21-low B cells have been identified 
in SLE, rheumatoid arthritis, and cryoglobulinemia, suggesting a 
role for these cells in the pathogenesis of autoimmunity (28–30). 
Most CVID patients present with elevated BAFF levels (27). Of 
note, increased BAFF levels sustain the expansion of CD21-low 
B cells in CVID (31). Moreover, studies show that overexpression 
of BAFF in mice leads to B-cell hyperplasia, splenomegaly, and 
autoimmunity (32, 33). Different genetic mutations, including 
TACI, ICOS, BAFF-R, CD20, and CD21 have been associated 
with increased risk of developing CVID (34–40). Among these 
genetic alterations, autoimmunity is most common in TACI 
alterations [18/50 (36%) vs. 112/490 (23%) in wt TACI CVID], 
in particular, heterozygous C104R mutations (11/20 patients, 
55%) (41).
PRKCD Deficiency
A CVID-like disorder associated with multiple features of 
immune dysregulation, including glomerulonephritis, lym-
phadenopathy, relapsing polychondritis, and antiphospholipid 
syndrome has been recently described in a 12-year-old patient 
born to consanguineous parents of Turkish origin (42). Genetic 
studies revealed a mutation of PRKCD gene, leading to a complete 
absence of the protein. PRKCD deficiency has also been reported 
in three siblings with LES (Table  1) (43). PRKCD plays a key 
role in the regulation of cell survival, proliferation, and apoptosis 
(44). PRKCD deficiency in mice seems to be related to a defective 
deletion of autoreactive B cells during B-cell development, due 
to impaired proapoptotic extracellular signal-regulated kinase 
signaling (45, 46).
LRBA Deficiency
LPS-responsive beige-like anchor protein (LRBA) deficiency 
is a novel PID caused by either homozygous or compound 
heterozygous mutations in LRBA that abolish LRBA protein 
expression. This PID is characterized by early onset hypogam-
maglobulinemia, autoimmune manifestations, susceptibility 
to IBD, and recurrent infections (47). However, it has been 
also described in patients with IBD with or without antibody 
deficiency (48, 49), in patients with autoimmune manifestations 
without hypogammaglobulinemia (50), or in patients with 
immune dysregulation, polyendocrinopathy, enteropathy, and 
X-linked syndrome (IPEX)-like disorder (51). The main clinical 
manifestations of LRBA deficiency are immune dysregulation 
(95%), followed by organomegaly (86%) and recurrent infec-
tions (71%). The most common autoimmune manifestations 
are enteropathy (59%), AHA (50%), and ITP (50%). A lower 
number of patients presented granulomatous-lymphocytic 
interstitial lung disease (36%), T1D or neutropenia (22%), 
chronic autoimmune hepatitis (13%), eczema and uveitis (9%), 
and alopecia (4.5%) (Table 1). LRBA is a highly conserved multi-
domain protein implicated in regulating endosomal trafficking, 
cell proliferation, and survival. LRBA deficiency is associated 
with increased apoptosis and altered phenotype of Treg cells, 
which express lower levels of key effector proteins involved in 
Treg cell suppression, such as CD25 and CTLA-4. This results 
in decreased frequency, aberrant phenotype, and decreased 
suppressive function of such cells. These alterations might play 
a critical role in the ubiquitous autoimmune manifestations of 
the disease.
CTLA-4 Haploinsufficiency
CTLA-4 haploinsufficiency has been recently associated with 
lymphoproliferation, lymphocytic infiltration, autoimmunity, 
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peripheral B-cell lymphopenia, hypogammaglobulinemia, and 
increased CD21lo B cells (52). In mouse models, homozygous 
CTLA-4 deficiency leads to a lethal autoimmune phenotype char-
acterized by multiorgan lymphocytic infiltration and destruction 
(53, 54) resambling FOXP3 deficiency (55–57). CTLA-4 plays a 
key role in immune tolerance. Recent studies show that CTLA-4 
is able to suppress the expression of CD80 and CD86 from antigen 
presenting cells (APCs) via transendocytosis (58). The depletion 
of the costimulatory ligands reduces T cell activation (59).
Activated Phosphoinositide 3-Kinase  
δ Syndrome
Activated phosphoinositide 3-kinase δ syndrome (APDS) 1 and 2 
are PID resulting from autosomal dominant mutations in PI3KCD 
and PIK3R1, respectively (60, 61). Autoimmune manifestations 
are reported in 34% of APDS1 patients. The clinical manifesta-
tions included cytopenias (AHA or tri-lineage cytopenia), glo-
merulonephritis, exocrine pancreatic insufficiency, autoimmune 
thyroid disease, seronegative arthritis, recurrent pericarditis, 
sclerosing cholangitis, and gastrointestinal nodular mucosal 
lymphoid hyperplasia (61). Autoimmune manifestations have 
been reported in the 17% of the APDS2 patients. They included 
ITP, AHA, Evans syndrome, T1D, chronic arthritis, autoimmune 
hepatitis, and chronic eczema (60). PI3Kδ is implicated in the 
regulation of Treg cell function. Studies suggest that PI3K is 
an important target for the treatment of different autoimmune 
conditions.
Hyper-igM Syndrome
Hyper-IgM syndrome (HIGM) is a group of disorders character-
ized by alterations of immunoglobulin receptor isotype switch-
ing, leading to normal or elevated IgM antibody and very low 
IgA, IgG, and IgE antibodies (62). Alterations in different genes 
implicated in CD40-CD40L pathway involved in B cell activa-
tion, class switch recombination or somatic hypermutation have 
been identified in HIGM. Seven different forms of HIGM have 
been till now described. Most of the cases (65–70%) are due to 
mutations of the gene encoding for CD40 ligand (CD40L) on the 
X chromosome, leading to HIGM1 (63). The other forms are due 
to mutations of AID (HIGM2), CD40 (HIGM3), UNG (HIGM5), 
NEMO (HIGM6), and IkBα (HIGM7). No genetic defect has 
been so far identified for HIGM4.
Autoimmunity has been described in all forms of HIGM. 
HIGM1 patients have an increased risk to develop IBD, seron-
egative arthritis, hypothyroidism, and SLE (64). In the 21% 
of patients affected with HIGM2 autoimmune hepatitis, ITP, 
T1D, IDB, and uveitis have been described (65). In addition, 
in patients with NEMO defects, AHA, IBD, and arthritis have 
been described (Table  1) (66). Studies on transgenic mouse 
models suggest that CD40–CD40L interactions is involved in 
the elimination of autoreactive B cells (67). In fact, an increase 
of circulating polyreactive B cells and a significant decrease of 
CD25+Foxp3+Treg cells have been reported in CD40L-deficient 
patients suggesting defects of the peripheral B-cell tolerance 
mechanism. An imbalanced production of cytokines, includ-
ing as IL-1, IL-8, IL-6, IL-10, IL-12, and tumor necrosis factor 
(TNF)-α may be observed in CD40-deficient patients (68). This 
impairment is the consequence of the involvement of CD40–
CD40L interaction in T-cell dependent macrophage-mediated 
immune response, implicated in the maturation of dendritic cells 
and regulation of the T-cell activation. The transcription factor 
NFkB plays a key role in the regulation of pro-inflammatory 
responses. Recent studies suggest that gut epithelial cells are 
directly implicated in the control of epithelial integrity and 
the regulation of the interaction between the mucosal immune 
system and gut microflora. In mice, NEMO deficiency causes a 
severe chronic intestinal inflammation, which has been associ-
ated with apoptosis of colonic epithelial cells, impaired expres-
sion of antimicrobial peptides, and translocation of bacteria 
into the mucosa. The chronic inflammatory response observed 
within the colon, is dominated by innate immune cells, as sug-
gested by the upregulation of IL1b, IL6, TNF, and Ccl2 and by the 
infiltration of large numbers of dendritic cells and granulocytes 
in the colon. Eventually, also T lymphocytes are involved, as 
suggested by the presence of lymphoid follicles and a massive 
infiltration with CD4+ T cells in the gut mucosa.
COMBineD iMMUnODeFiCieCieS
Severe combined immunodeficiency (SCID) is a group of dif-
ferent PIDs characterized by a severe deficiency of the cellular 
and humoral immune system. SCID phenotype may be due to a 
variety of different mutations. From a clinical point of view, SCID 
is characterized by recurrent severe infections, chronic diarrhea, 
and failure to thrive (69, 70). The clinical presentation may drive 
the diagnosis toward a specific molecular cause of SCID (69). 
Patients affected with SCID often develop autoimmune manifes-
tations. This may appear surprising in that SCID patients, who 
are unable to mount any immune response to foreign pathogens, 
may paradoxically develop autoimmune phenomena. Alterations 
in both central and peripheral tolerance have been described in 
SCID patients (71).
Autoimmunity in Omenn Syndrome
Omenn syndrome (OS) is a SCID inherited in an autosomal 
recessive manner, caused by homozygous or compound het-
erozygous mutations in recombinase activating gene 1 (RAG1) 
or RAG2, implicated in V(D)J recombination, which represents 
a crucial step in T- and B-cell differentiation. OS has also been 
associated with hypomorphic mutations in other different genes, 
including RMRP, ADA, IL2RG, Artemis, DNA ligase IV, ZAP70, 
and IL-7Ra deficiency (72, 73). Signs of OS, including oligo-
clonal T-cell expansion, generalized rash, and lymphadenopa-
thy have been reported in some patient affected with DiGeorge 
syndrome. This rare condition is known as atypical complete 
DiGeorge syndrome (74). Apart from recurrent infections, 
patients affected with OS also show features of autoimmunity, 
including erythrodermia, alopecia, hepatosplenomegaly, and 
lymphadenopathy (Table  2). The hallmark of the syndrome 
is the expansion and activation of a peripheral oligoclonal 
population of autoreactive T cells, due to defective central (75, 
76) and peripheral tolerance mechanisms (77). Studies suggest 
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that in OS, defective AIRE expression may lead to inadequate 
expression of tissue-specific self-antigens by mTEC, impairing 
central tolerance. In these patients, the T-cell compartment is 
composed by a high proportion of autoreactive T cells, which 
are able to expand in peripheral tissues leading to the clinical 
symptoms. Similarly, alterations in central tolerance may be 
implicated in the pathogenesis of immune manifestations also 
in PIDs characterized by ineffective thymopoiesis, such as the 
DiGeorge syndrome or in SCID characterized by partial defects 
of the T-cell maturation, such as IL-7alfa, common γ chain, or 
ARTEMIS defects. The persistent infectious/inflammatory state 
and the presence of immunologic “space,” which increases the 
ability of T cells to respond to an excess of cytokines or antigens, 
impairs peripheral tolerance in SCID patients. Treg population 
may be also affected in SCID patients.
Autoimmune Manifestations in SCiD 
Due to iL7R Mutations
IL7Ra deficiency is responsible of the majority of T-B+NK+ cases 
(72) characterized by an increased susceptibility to severe and 
opportunistic infections. In a few cases, autoimmune manifesta-
tions have been reported (72, 73). Autoimmune manifestations 
presented with OS in one infant (73), and cytopenias in three 
other cases. Autoimmune cytopenias have been also described 
in some patients with PNP-deficiency, and mutations of ADA, 
DNA ligase IV, Cernunnos, and hypomorphic RAG1 mutations 
(Table 2) (69, 78–82).
Ca++ Channellopathies Due to 
Mutations in ORAi1 and STiM1
Null or loss-of-function mutations in ORAI1 or STIM1 are 
associated with a SCID-like disease characterized by recurrent 
and chronic infections, autoimmunity, ectodermal dysplasia, 
and muscular hypotonia in the presence of numerically intact 
T, B, and NK cells. Symptoms usually manifest in the first year 
of life. Lymphoproliferation, AHA, and ITP are very common in 
patients with STIM1 mutations (Table  2). Autoimmunity may 
derive from alterations of negative selection of autoreactive T cells 
and/or B cells during their development. In fact, Ca2+ signals 
are implicated in TCR and BCR signaling and thus potentially 
influence the selection thresholds in immature T and B cells. 
Moreover, a reduced frequency of Treg cells has been observed in 
STIM1-deficient patients (83, 84) and in one patient with ORAI1 
p.R91W mutation.
SYnDROMeS wiTH iMMUnODeFiCienCY
wiskott–Aldrich
Wiskott–Aldrich syndrome is a very rare immunodeficiency, 
characterized by thrombocytopenia, eczema, and recurrent 
bacterial infections appearing in the first months of life. Other 
features includes humoral and cellular immunodeficiency, 
defects of the innate immunity (85–87), increased risk to 
develop autoimmune manifestation and malignancies, impaired 
apoptosis (88, 89), and defective cell motility (90). The gene 
responsible for WAS (WASP) is located on the X chromosome 
and encode for WASP protein, which is only expressed in the 
cytoplasm of hematopoietic cells. WASP protein plays a major 
role in the transduction of the signals from the cell surface to 
the actin cytoskeleton, which regulates actin polymerizationand 
the formation of actin filament (91, 92). WAS patients are at 
a higher risk of developing autoimmunity and most of WAS 
patients (about 40%) are affected by at least one autoimmune 
manifestation (93, 94). The most common autoimmune manifes-
tations include AHA, autoimmune neutropenia, vasculitis, and 
IgA nephropathy with or without the association with Henoch–
Schönlein purpura, polyarthritis and IBD (Table 2) (87, 93–95). 
Studies suggest that a defect in Treg cells could be implicated in 
the pathogenesis of autoimmune manifestations (96, 97). In fact, 
Treg cells, isolated from WAS patients, show a reduced ability to 
suppress effector T-cell proliferation and IFN-γ production (98, 
99). On the contrary, Treg cell development is not impaired in 
these patients. In addition, Treg cells from WASp−/− mouse show 
a reduced granzyme B secretion, which results in the inability to 
suppress B-cell proliferation and apoptosis. Furthermore, studies 
on mouse models show that Treg cells from WASp−/−mouse are 
not able to prevent the development of autoimmunity in scurfy 
mice (Foxp3-deficient) (98–100). Also B cells may be implicated 
in the pathogenesis of autoimmune manifestations in WAS 
patients. Studies show that selective deletion of WASP in B cells 
leads to the production of autoantibodies and the development 
of autoimmunity (101, 102).
DiGeorge Syndrome
Autoimmune manifestations have been reported in about 
the 10% of patients with DiGeorge syndrome (103–105). 
Autoimmune disorders include mainly autoimmune cytopenias 
(ITP, AHA) (106–108), autoimmune arthritis (107), autoim-
mune hepatitis, vitiligo, IDB, and autoimmune endocrinopathy 
(Table 2) (109). Impaired T-cell development in an abnormal 
thymus may result in altered central tolerance and escape of 
self-reactive T. Thymic abnormality may also result in impaired 
generation of Treg (96, 110, 111).
Ataxia Telangiectasia
Patients with ataxia telangiectasia (A-T) have increased fre-
quency of autoimmune disorders (112), including psoriasis and 
autoimmune thyroid disease (Table 2). Loss of suppressor T-cell 
function has been described as responsible for the development 
of autoimmune disease.
STAT1 Gain of Function
Increased incidence of autoimmunity has been reported in 
heterozygous STAT1 gain-of-function (GOF) mutations (113). 
The main clinical features of the syndrome include chronic 
mucocutaneous candidiasis (CMC) (114–118), disseminated 
coccidioidomycosis, and histoplasmosis (116, 119), recurrent 
sinopulmonary infections and pneumonias (with or without 
bronchiectasis), herpes virus infections, blood-borne infections, 
squamous cell cancer, and cerebral aneurysms (116, 120). The 
most common autoimmune manifestation is thyroiditis, but in 
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some case patient may show an IPEX-like phenotype (121). 
Number and function of Treg cells are usually normal and the 
pathogenesis of IPEX-like disease remains unclear (121).
STAT3 Gain of Function
Recent studies show that activating STAT3 mutations may lead to 
autoimmunity, hypogammaglobulinemia, lymphoproliferation, 
and mycobacterial disease (122). The autoimmune manifesta-
tions are early onset and include neonatal diabetes and some 
rare disorders, such as desquamative interstitial pneumonitis 
and posterior uveitis (123). Patients with activating STAT3 
mutations show a reduced number of Th17 cells, decreased IL-17 
production, and deficiency of Treg, NK, and dendritic cells (123). 
Autoimmunity may develop as a consequence of the impaired 
Treg development.
COnCLUSiOn
Autoimmunity and immunodeficiencies represent two oppo-
site conditions, which may coexist in the context of a general 
immune dysregulation. Even though different mechanisms have 
been identified to explain autoimmunity in PIDs, the pathogen-
esis of autoimmunity remains unexplained in most of the cases. 
Considering this strong association, underlying immunodifiency 
should be always excluded in particular in presence of early onset 
or multiple autoimmune manifestations (124).
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